MiniMed Group (NASDAQ:MMED – Get Free Report) was upgraded by equities researchers at Benchmark to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.
Several other research firms have also weighed in on MMED. Zacks Research upgraded shares of MiniMed Group to a “hold” rating in a research note on Thursday, April 9th. Piper Sandler initiated coverage on shares of MiniMed Group in a research note on Tuesday, March 31st. They issued a “neutral” rating and a $16.00 price target on the stock. Barclays initiated coverage on MiniMed Group in a research report on Wednesday, April 1st. They set an “overweight” rating and a $26.00 price objective for the company. Wall Street Zen raised MiniMed Group to a “hold” rating in a research report on Saturday, March 14th. Finally, Wells Fargo & Company assumed coverage on MiniMed Group in a research note on Tuesday, March 31st. They set an “overweight” rating and a $26.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.25.
View Our Latest Analysis on MiniMed Group
MiniMed Group Price Performance
About MiniMed Group
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.
Recommended Stories
- Five stocks we like better than MiniMed Group
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for MiniMed Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiniMed Group and related companies with MarketBeat.com's FREE daily email newsletter.
